# CytomX Therapeutics Inc. (CTMX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.18, market value $475 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). CytomX Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 26.0×**. Each dollar of revenue is priced at 26.0×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -17.4%** (5-yr avg -62.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -476.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -22.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -17.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -78.3%**. Return on all capital, debt included, is -78.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -52.6%**. Each dollar of assets produces -52.6% of profit.

## Growth
- **Revenue growth (1 yr): -44.8%** (3-yr 12.8%/yr, 5-yr 2.2%/yr). Revenue fell 44.8% over the last year, against 2.2% a year compounded over five years: growth is slowing.

## Financial health
- **Debt to equity: 0.02**. Debt is 0.02 times equity: a conservative balance sheet.
- **Current ratio: 3.09** (quick 3.09). Current assets cover the next year's liabilities 3.09 times.
- **Altman Z-score: 7.12**. A Z-score of 7.12 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. CytomX Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -44.5%** (YTD -48.8%, 3-mo -34.3%). The shares are down 44.5% over twelve months including dividends.
- **From 52-week high: -73.4%** (1.9% above the low). Trading 73% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 37**. An RSI of 37 is neutral.
- **Beta (1 yr): 1.77** (volatility 87%). Beta of 1.77 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CTMX · Page: https://foliofundamentals.com/stocks/ctmx

Not investment advice.